Skip to content

US · TNDM · MEDICAL - DEVICES

Tandem Diabetes Care, Inc. (TNDM) intrinsic value and stock valuation

$17.46as of 2026-11-21 · Mkt cap 1.53B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tandem Diabetes Care, Inc. DCF and intrinsic value

InvestorsCraft values TNDM with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from TNDM’s statements →

Tandem Diabetes Care, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices San Diego, CA 92130 tandemdiabetes.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.01B+15.3% 5y CAGRd
20112025
Net income
-$-204.71M
20112025
Free cash flow
-$-29.67M
20112025
Total equity
$155.2M-15.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.01B$940.2M$747.7M$801.2M$702.8M
Operating income-$-78.12M-$-99.13M-$-233.23M-$-92.85M$22.7M
Net income-$-204.71M-$-96.03M-$-222.61M-$-94.59M$15.6M
EPSd-$-3.04M-$-1.47M-$-3.43M-$-1.47M$242K
Operating cash flow-$-9.72M$24.2M-$-31.81M$50.5M$111.4M
Capital expenditure-$-19.95M-$-19.23M-$-26.8M-$-34.1M-$-23.51M
Free cash flow-$-29.67M$4.99M-$-58.61M$16.4M$87.9M
Total assets$881.1M$967.7M$952.7M$1.05B$905.1M
Total debt$444.5M$473.6M$415.7M$419.9M$314.7M
Net debt$353.8M$404.3M$356.8M$247.4M$243.5M
Total equity$155.2M$263.1M$313.6M$440M$433.1M
Cash and short-term investments$292.7M$438.3M$467.9M$616.9M$623.8M
Income statement
20252024202320222021
Revenue$1.01B$940.2M$747.7M$801.2M$702.8M
Cost of revenue$483.9M$450.6M$380M$388.2M$326.6M
Gross profit$530.9M$489.6M$367.7M$413M$376.2M
Research and development expenses$174.8M$198.9M$248.4M$170.2M$92.1M
Selling, general and administrative expenses$434.1M$389.8M$352.5M$335.7M$261.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$609M$588.7M$600.9M$505.8M$353.6M
Cost and expenses$1.09B$1.04B$981M$894.1M$680.2M
Interest income$9.09M$18M$22.9M$6.06M$670K
Interest expense$7.91M$7.42M$9.88M$6.21M$6.04M
Depreciation and amortization$17.7M$160K$15.7M$14.3M$13.9M
Ebitda-$-174.7M-$-99.13M-$-196.46M-$-74.21M$34.1M
Operating income-$-78.12M-$-99.13M-$-233.23M-$-92.85M$22.7M
Total other income/expenses, net-$-122.15M$7.26M$13M-$0.00-$-6.75M
Income before tax-$-200.27M-$-91.87M-$-220.25M-$-92.85M$15.9M
Income tax expense$4.44M$4.16M$2.36M$1.74M$340K
Net income-$-204.71M-$-96.03M-$-222.61M-$-94.59M$15.6M
Weighted average shares outstanding$67.3M$65.5M$64.9M$64.2M$63M
Weighted average diluted shares outstanding$67.3M$65.5M$65M$64.2M$64.4M
Balance sheet
20252024202320222021
Cash and short-term investments$292.7M$438.3M$467.9M$616.9M$623.8M
Net receivables$165.5M$114.6M$105.6M$114.7M$110.7M
Inventory$128.8M$149.6M$157.9M$111.1M$68.6M
Total current assets$618.1M$724.5M$748M$850M$811.5M
Property, plant and equipment, net$179.8M$163.5M$164.3M$179.2M$77.9M
Goodwill and intangible assets$0.00$930K$2.78M$4.63M$6.64M
Long-term investments$60.4M$74.6M$0.00$0.00$0.00
Total non-current assets$263M$243.2M$204.7M$202.8M$93.6M
Total assets$881.1M$967.7M$952.7M$1.05B$905.1M
Accounts payable$47.1M$44.7M$49.6M$55.7M$28M
Short-term debt$19.5M$58.9M$17.1M$13.1M$9.28M
Deferred revenue$9.53M$11.8M$44M$18.8M$10.2M
Total current liabilities$242.7M$247.1M$195.3M$165.3M$131.9M
Long-term debt$425M$414.7M$398.6M$406.8M$305.4M
Deferred revenue, non-current$8.47M$10.5M$13.3M$16.9M$16.9M
Total non-current liabilities$483.2M$457.5M$443.8M$447.6M$340.2M
Capital lease obligations$134.4M$124.6M$130.6M$136.7M$33.2M
Total liabilities$725.9M$704.6M$639M$612.8M$472M
Common stock$70K$70K$70K$70K$60K
Retained earnings-$-1.25B-$-1.05B-$-951.8M-$-729.19M-$-634.6M
Accumulated other comprehensive income (loss)$5.59M-$-1.95M$1.37M-$-1.82M-$-620K
Total equity$155.2M$263.1M$313.6M$440M$433.1M
Total investments$262.4M$443.6M$409M$444.4M$552.6M
Total debt$444.5M$473.6M$415.7M$419.9M$314.7M
Net debt$353.8M$404.3M$356.8M$247.4M$243.5M
Cash flow statement
20252024202320222021
Net income-$-204.71M-$-96.03M-$-222.61M-$-94.59M$15.6M
Depreciation and amortization$13.8M$16.6M$15.7M$14.3M$13.9M
Stock-based compensation$92.4M$101.4M$88.1M$84.9M$60.8M
Change in working capital-$-23.04M-$-11.78M-$-17.68M-$-4.65M$14.4M
Accounts receivable-$-56.81M-$-20.8M$4.28M-$-7.83M-$-30.98M
Inventory$24.8M$5.81M-$-46.05M-$-42.45M-$-4.95M
Accounts payable$2.23M-$-2.39M-$-4.86M$24.5M$10.3M
Net cash provided by operating activities-$-9.72M$24.2M-$-31.81M$50.5M$111.4M
Investments in property, plant and equipment-$-19.95M-$-19.23M-$-26.8M-$-34.1M-$-14.18M
Acquisitions, net$0.00$0.00-$-69.5M-$-25.72M$0.00
Net cash used for investing activities$72.9M-$-23.48M-$-85.74M$33.2M-$-186.88M
Common stock issued-$-2.61M-$-6.73M$0.00$17.6M$0.00
Common stock repurchased$0.00-$-30M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-43.37M$8.37M$4.11M$16.9M$51.9M
Net change in cash$21.4M$10.4M-$-113.65M$101.3M-$-23.43M
Cash at end of period$90.6M$69.2M$58.9M$172.5M$71.2M
Operating cash flow-$-9.72M$24.2M-$-31.81M$50.5M$111.4M
Capital expenditure-$-19.95M-$-19.23M-$-26.8M-$-34.1M-$-23.51M
Free cash flow-$-29.67M$4.99M-$-58.61M$16.4M$87.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tandem Diabetes Care, Inc.

        Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

        CEO
        John F. Sheridan
        Employees
        2.5K
        Beta
        1.58

        Explore

        Frequently asked questions

        What is the intrinsic value of Tandem Diabetes Care, Inc. (TNDM)?

        Tandem Diabetes Care, Inc. (TNDM) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TNDM undervalued?

        TNDM trades at a price of $17.46 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.